Viatris (VTRS) News Today $9.86 +0.16 (+1.65%) Closing price 08/11/2025 04:00 PM EasternExtended Trading$10.00 +0.14 (+1.42%) As of 08/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTRS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Viatris Earnings Call: Growth Amid Challenges4 hours ago | theglobeandmail.comWhy Viatris (VTRS) Stock Is Up TodayAugust 11 at 4:22 PM | msn.comViatris stock rises after FDA approval of first generic iron sucroseAugust 11 at 11:20 AM | investing.comViatris Shares Climb Following FDA Clearance of First Generic Iron Sucrose InjectionAugust 11 at 11:20 AM | msn.comViatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.August 11 at 9:29 AM | prnewswire.comViatris Expands Board with New AppointmentAugust 8, 2025 | theglobeandmail.comViatris (NASDAQ:VTRS) Beats Q2 Sales Targets, Stock SoarsAugust 8, 2025 | msn.comViatris Inc. (VTRS) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comXanax-maker Viatris beats quarterly profit, revenue estimates; shares riseAugust 7, 2025 | reuters.comViatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial GuidanceAugust 7, 2025 | prnewswire.comViatris Q2 earnings on deck: What to expectAugust 6, 2025 | msn.comViatris Stock: Analyst Estimates & RatingsAugust 6, 2025 | msn.comViatris (VTRS) Reports Earnings Tomorrow: What To ExpectAugust 6, 2025 | finance.yahoo.comViatris Announces Quarterly DividendAugust 5, 2025 | prnewswire.comViatris Announces Appointment of David Simmons to the Company's Board of DirectorsAugust 5, 2025 | prnewswire.comViatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 ConferenceAugust 1, 2025 | prnewswire.comQ1 Earnings Highs And Lows: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals StocksJuly 29, 2025 | msn.comCovering The Flaws In The Viatris Undervaluation ArgumentJuly 23, 2025 | seekingalpha.comWhat to Expect From Viatris' Next Quarterly Earnings ReportJuly 23, 2025 | msn.com1 Cash-Producing Stock with Exciting Potential and 2 We Brush OffJuly 22, 2025 | finance.yahoo.comViatris Inc.: Viatris Provides Update on Phase 3 Study of MR-139 for BlepharitisJuly 18, 2025 | finanznachrichten.deWhy Viatris (VTRS) Stock Is Falling TodayJuly 18, 2025 | msn.comViatris Hits Snag In Eye Drug Study—Phase 3 Plans Under ReviewJuly 18, 2025 | benzinga.comViatris eye ointment fails late-stage study for eye condition, shares fallJuly 18, 2025 | msn.comViatris eye ointment fails late-stage study, shares fallJuly 18, 2025 | reuters.comViatris down on late-stage trial setback for eye disorder therapyJuly 18, 2025 | msn.comViatris Shares Dip After Blepharitis Treatment Fails to Hit Main Study GoalJuly 18, 2025 | msn.comViatris Stock Tumbles as Eyelid Inflammation Treatment Misses TargetJuly 18, 2025 | barrons.comViatris eye therapy fails to meet late-stage trial goalJuly 18, 2025 | reuters.comViatris Provides Update on Phase 3 Study of MR-139 for BlepharitisJuly 18, 2025 | prnewswire.comViatris (VTRS) Announces Positive Top-line Results from VEGA-3July 17, 2025 | finance.yahoo.comViatris: A Contrarian Bet With Virtually No DownsideJuly 16, 2025 | seekingalpha.comViatris Certified as a Great Place to Work® in CanadaJuly 15, 2025 | finance.yahoo.com13 Best Low Priced Pharma Stocks to Buy NowJuly 15, 2025 | insidermonkey.comViatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharmaJuly 15, 2025 | finance.yahoo.comGoldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PTJuly 11, 2025 | insidermonkey.comJ&J wins appeals court ruling against Teva and Viatris in patent dispute over neuro drugJuly 9, 2025 | msn.comThe 5 Most Interesting Analyst Questions From Viatris’s Q1 Earnings CallJune 27, 2025 | msn.comViatris Inc.: Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in PresbyopiaJune 26, 2025 | finanznachrichten.deTheravance higher as China approves Viatris-partnered COPD therapyJune 26, 2025 | msn.comViatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in PresbyopiaJune 26, 2025 | prnewswire.comViatris: The Problem With The Business ModelJune 25, 2025 | seekingalpha.com3 Reasons to Avoid VTRS and 1 Stock to Buy InsteadJune 17, 2025 | msn.comViatris to Report Second Quarter 2025 Financial Results on August 7, 2025June 12, 2025 | prnewswire.comKuehn Law Encourages Investors of Viatris Inc. to Contact Law FirmJune 10, 2025 | globenewswire.comVTRS Q1 Earnings Call: Pipeline Advances, Tariff Risks, and Strategic Cost ReviewJune 10, 2025 | msn.comViatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference TranscriptJune 9, 2025 | seekingalpha.comGoldman Sachs Initiates Coverage of Viatris (VTRS) with Neutral RecommendationJune 7, 2025 | msn.comViatris (VTRS) Faces Securities Fraud Class Action Over FDA Inspection FalloutJune 6, 2025 | insidermonkey.comViatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference TranscriptJune 5, 2025 | seekingalpha.com Get Viatris News Delivered to You Automatically Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter. Email Address VTRS Media Mentions By Week VTRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VTRS News Sentiment▼0.460.47▲Average Medical News Sentiment VTRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VTRS Articles This Week▼1914▲VTRS Articles Average Week Get Viatris News Delivered to You Automatically Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Pfizer News BeOne Medicines News BioNTech News Summit Therapeutics News Insmed News Teva Pharmaceutical Industries News Genmab A/S News Dr. Reddy's Laboratories News Ascendis Pharma A/S News Qiagen News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VTRS) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredSell these stocks now—what to buy insteadWall Street veteran Marc Chaikin—creator of the Power Gauge system—is warning that “smart money” is rapidly pu...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viatris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viatris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access